Home - Research activities

The main research efforts of the Molecular Carcinogenesis Group (MCG) are devoted to deciphering the molecular mechanisms and their deregulations that are responsible for the development of neoplastic disease.

Specifically, the MCG has long been involved in the investigation of mechanisms leading to deregulation of the cell cycle and emergence of genomic instability in cancer. In this frame, aberrations in the pRb/E2F, DNA damage response and repair (DDR-R) and p53 pathways/networks have been the targets of intense research examination. By employing a dually linked approach, starting from observations obtained from clinical specimens and extending to functional recapitulations, the role and/or deregulations of components of the above pathways and networks are being investigated in relation to the outcome on the cell cycle (cell proliferation, apoptosis, senescence) and genome integrity.

A second research field that MCG has been involved in is the investigation of mechanisms responsible for arteriosclerosis-atherogenesis, since certain pathways/networks involved in neoplasia development as well as inflammation participate also in these non-malignant diseases. Particularly, the role of p53 in the senescence-associated ICAM-1 overexpression, in a NF-κB independent manner, was examined in atherosclerotic lesions. Also, studies on deregulations of pathways involved in the production of free radicals and NF-κB dependent signaling pathways have been performed in this pathological condition.

Finally, MCG has been working on inflammation and infectious agents in neoplastic and non-neoplastic disease. Regarding neoplastic diseases the contribution of infectious agents, like HPV and EBV, in the development of various malignant diseases has been investigated. Additionally, associations between mycobacteria and sarcoidosis development as well as the genetic background of patients with inflammatory bowel diseases have also been examined.

Apart from the research activities, MCG is an active member the last years in the European Society of Pathology by participating in the annually K-ras European Quality Assurance Program, related to the anti-EGFR therapy.

VG New

Prof. Vassilis G. Gorgoulis

Laboratory of Histology-Embryology
Molecular Carcinogenesis Group
Medical School
National and Kapodistrian University of Athens

 

Biomedical Research Foundation of the Academy of Athens

 

Faculty Institute for Cancer Sciences, University of Manchester,
Manchester Academic Health Science Centre, Manchester, UK

Manchester Centre for Cellular Metabolism,
University of Manchester, Manchester Academic Health Science Centre, Manchester

 

EMBO member

 

 

 

Office Tel: 0030 210-7462352
Fax: 0030 210-7462340
E-mail: [email protected]

News

Also see...

Copyright ©2011-2015, Prof. Gorgoulis Powered by AVMap